TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Corticosteroid Dosage for Crohn's Disease Flare

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18~* Established diagnosis of Crohn's disease~* Diagnosis of Crohn's flare~* Decision by treating gastroenterologist to start corticosteroid therapy~Exclusion Criteria:~* Patients in whom corticosteroid therapy is contraindicated: immunocompromised (active cancer on chemotherapy or radiation treatment), severe liver disease (decompensated cirrhosis, active alcoholic hepatitis), end-stage renal disease on dialysis, AIDS or AIDS-defining illness; myocardial infarction within the past year; NYHA Class 4 heart failure~* Patients on systemic corticosteroid therapy currently or within the past 8 weeks~* Patients not on stable doses of immunomodulators or biologics for at least 8 weeks~* Infectious colitis (e.g., C. difficile, CMV, HSV)~* Systemic infections (bacteremia, fungal infections)~* Fulminant Crohn's disease~* Patients who require imminent surgery~* Abscess~* Pregnancy~* Weight \<35 kg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Weight-based (Type: ACTIVE_COMPARATOR): Corticosteroid dose weight-based at equivalent to 1mg/kg prednisone daily.
- Fixed dose (Type: ACTIVE_COMPARATOR): Corticosteroid dose fixed at equivalent to 40mg prednisone daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Development of a Surgical Localizing Aid Medical Device

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be undergoing a radiological imaging, such as planar X-ray, fluoroscopy, CT or MRI~Exclusion Criteria:~* Subjects who may have allergies to medical skin adhesives, medical skin inks or copper metal

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Target Tape (Type: NO_INTERVENTION): Including target tape in the procedure
- Control (Type: OTHER): Without target tape in the procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of angioimmunoblastic T-cell lymphoma (recurrent or refractory) based on histologic examination.~* At least one objective measurable or evaluable disease parameter.~* Have failed at least one type of treatment: chemotherapy, auto-transplant, or steroid treatment. Patients may not receive concurrent chemotherapy.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.~* Adequate renal function as indicated by creatinine \<= 1.5 the upper limit of normal (ULN).~* Adequate liver function as indicated by alkaline phosphatase, Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) \<= 2x the upper limit of normal.~* Total bilirubin \<= 2x the upper limit of normal.~* Age 18 or older.~Exclusion Criteria:~* Prior cyclosporine or Tacrolimus (FK506).~* Prior allogeneic transplant.~* Evidence of active infection.~* Congestive heart failure, kidney failure, liver failure, or other severe co-morbidities.~* Evidence of active neurological impairment.~* Previous history of hypersensitivity to cyclosporine and/or Cremorphor EL (polyoxyethylated oil).~* History of other malignancies (other than cured carcinomas in situ of the cervix or basal cell carcinoma of the skin).~* pregnant or breastfeeding women.~* Human immunodeficiency virus (HIV) positive.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cyclosporine (Type: EXPERIMENTAL): High dose cyclosporine weeks 1-6, then maintenance dose cyclosporine weeks 7-36. If CR, PR, or SD at week 36 evaluation, treatment is complete. If progression occurs during weeks 7-36, patients will re-register to Step 2 at time of PD and begin high dose therapy (weeks 1-6), followed by maintenance therapy (weeks 7-36). At second progression patients will end protocol treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with pulmonary arterial hypertension with New York Heart Association stage II - III disease will be eligible for recruitment in the patient portion of the trial. Interested healthy age matched volunteers will also be recruited.~Exclusion Criteria:~* Patients and volunteers will be excluded if they have significant co-morbidities including other cardiorespiratory disease, metabolic abnormalities including diabetes or thyroid disorders. They will be excluded if they cannot safely exercise and perform a six minute walk test or if they are wheelchair bound.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- PH with wasting (Type: None): This group of patients with idiopathic pulmonary arterial hypertension exhibit quadriceps wasting
- PH no wasting (Type: None): This groups of patients with idiopathic pulmonary arterial hypertension exhibit no evidence of muscle wasting
- Controls (Type: None): This group of volunteers does not have pulmonary arterial hypertension and would not be expected to have muscle wasting

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Fluoroscopic and RSA Evaluation of the Triathlon Total Knee Prosthetic Design

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient (minimum age of 18 years old, no maximum age limit) is diagnosed with osteoarthritis or rheumatoid arthritis and requires primary arthroplasty.~* Patient is capable of giving informed consent and expressing a willingness to comply with this study~* Patient has no major deformities (i.e. sagittal and coronal deformities are less then 15 degrees)~* The ability to perform a lunge and step-up motion without the help of bars or a cane.~* No or slight pain during activity according to the Knee Society Pain Score~Exclusion Criteria:~* The patient is unable or unwilling to sign the Informed Consent specific to this study~* The individual has a functional impairment of any other lower extremity joint besides the operated knee~* Patient has a flexion contracture of 15° and more~* Patient has a varus/valgus contracture of 15° and more~* Patients requiring revision arthroplasty~* The patient does not understand the Dutch or English language good enough to participate.~* The use of walking aids~* The inability to walk more than 500 meters

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Triathlon Mobile-bearing (Type: EXPERIMENTAL): Primary total knee replacement with cemented Triathlon posterior stabilized mobile-bearing
- Triathlon Fixed-bearing (Type: ACTIVE_COMPARATOR): Primary total knee replacement with cemented Triathlon posterior stabilized fixed-bearing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study to See How Safe Curcumin is and How Well it Works When Used to Treat Mucositis in Patients Getting Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ grade 2 oral mucositis related to chemotherapy for cancer~* Ability to understand and the willingness to review and sign a written informed consent document.~* ≥ 18 years of age~* Willingness to use adequate contraception prior to study entry, for the duration of study participation and for 30 days after the last dose for women of child-bearing potential and men~Exclusion Criteria:~* Current use of therapeutic doses of anticoagulants such as warfarin or antiplatelet agents (prophylactic doses and agents are acceptable)~* Biliary tract obstruction or cholelithiasis~* History of gastric or duodenal ulcers or hyperacidity syndromes~* AST or ALT \> 2 x ULN~* Total bilirubin ≥ 2 x ULN~* INR \> 1.5~* Previous stem cell transplant (allogeneic or autologous)~* Preexisting oral disease, such as active oral infection, trauma to the oral mucosa or oral - ulceration prior to chemotherapy~* Known allergy/hypersensitivity to curcumin, yellow food coloring, or other members of the - Zingiberaceae (ginger) family~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mouthwash-standard pharmacy preparation (Type: ACTIVE_COMPARATOR): Standard mouth wash preparation administered by ingested mouth rinse three times per day.~The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine.
- Curcumin (Type: EXPERIMENTAL): Curcumin (BCM-95) administered by ingested mouth rinse three times per day. Subjects will be in this arm at the previously determine maximum tolerated dose (MTD).
- Curcumin-MTD (Type: OTHER): Curcumin (BCM-95) administered by ingested mouth rinse. A total of 12-15 subjects will be in this arm to determine maximum tolerated dose (MTD).~There will be 3 participant at each of 4 does levels (0.33g, 1g, 2g, 3g) per rinse, three times daily for 4-6 weeks. (additional 3 subjects if a dose-limiting toxicity occurs)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Models of Auditory Hallucination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 - 45 years~* Voice hearing patients~* Meet diagnostic criteria for DSM-V schizophrenia or schizophreniform disorder~* Report hearing voices at least once a day~* Score \> 3 on PANSS P3 (hallucinations item)~Exclusion Criteria:~* DSM-V substance use disorder within the past 6 months~* Previous head injury with neurological symptoms and/or unconsciousness~* Intellectual disability (IQ \< 70)~* Non-English speaker~* Contraindications for TMS, including:~  * History of seizures~ * Metallic implants~ * Pacemaker~ * Pregnancy~* Less than 6 weeks of a stable dose of psychotropic medication(s)~* Comorbid mood or anxiety diagnosis~* Clinically/behaviorally instability and unable to cooperate with TMS procedures~* Clinically significant medical condition(s)~* Unstable medical condition(s) based on EKG, medical history, physical examination, and routine lab work~* Personal history of stroke~* Family history of seizures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- TMS to insula (Type: ACTIVE_COMPARATOR): This study will recruit 30 clinical voice hearers (P+H+). They will complete two parallel forms of the conditioned hallucinations task (with different visual and auditory stimuli) on two occasions, separated by a week.~TMS and sham will be delivered in a randomized counterbalanced order. Hypothesis: Inhibiting the insula will decrease prior over-weighting. If this computational perturbation is responsible for conditioned hallucinations, then ameliorating it with TMS that increases insula engagement will decrease conditioned hallucination responses. Furthermore, the prior weighting parameter will be reduced following active TMS compared with sham.
- TMS to cerebellum (Type: ACTIVE_COMPARATOR): This study will recruit a further 70 clinical voice hearers. Again, they will complete parallel forms of the conditioned hallucinations task on two occasions, separated by a week. They will receive excitatory TMS over the cerebellum (and sham on the other occasion, in a randomized counterbalanced order). Hypotheses: Exciting the cerebellum will increase belief-updating. If poor belief-updating contributes to conditioned hallucinations, increasing cerebellum engagement should decrease conditioned hallucinations and alter the belief-updating model parameter compared with sham TMS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Spatial Cognitive Training

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inability to perceive visual stimuli, i.e. no light perception, with stable visual loss over the past year~* The investigators anticipate that causes of blindness will be ocular, including:~  * glaucoma~ * diabetic retinopathy and macular degeneration~ * the most common causes of blindness in Veterans~ * as well as possibly late-onset Leber's optic atrophy and ocular trauma (in the absence of TBI)~* To minimize heterogeneity due to variations in age and the duration of visual loss, the investigators will restrict enrollment to Veterans and Non-Veterans over the age of 50 who lost light perception within the last 5 years, and who have completed standard O\&M training.~* From a practical standpoint, this also enables the investigators to focus on participants who can potentially benefit most from the proposed intervention.~Exclusion Criteria:~* Participants will be excluded if they have any neurological condition, such as:~  * TBI~ * history of blast exposure~ * stroke~ * brain tumors~ * epilepsy, etc.~* Participants will also be excluded if MRI scanning is contra-indicated, e.g.:~  * due to an implanted device such as a pacemaker~ * or foreign bodies of ferromagnetic nature~* Cognitive screening will be performed using the Repeatable Battery for Assessment of Neuropsychological Status (RBANS, Randolph, 1998) and participants with cognitive impairment will be excluded based on a score of 1.5 SD below the mean for the Verbal Memory Index.~* The investigators will test participants' hearing using a validated screening questionnaire (Screening Version of the Hearing Handicap Inventory for the Elderly, HHIE-S, Wentry \& Weinstein, 1983, Lichtenstein et al., 1988) followed by assessment of audiometric pure tone (0.5, 1.0, 2.0, 4.0 KHz) hearing thresholds in the CVNR sound booth.~* Participants with more than mild hearing loss (HHIE score \>8 or audiometric thresholds \>40dB) will be excluded (Wentry \& Weinstein, 1983; Wilson, 2009), given that the investigators are relying on audio cues.~* The investigators will also exclude visually impaired Veterans who are dependent on a wheelchair or scooter for mobility, as they will not be able to take part in the real-world task.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Training Group (Type: EXPERIMENTAL): Spatial training
- Control Group (Type: OTHER): Letter number matching

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Succinylcholine or Rocuronium for Rigid Bronchoscopy Under General Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients scheduled for an interventional rigid bronchoscopy under general anesthesia~Exclusion Criteria:~* pregnant woman or woman of childbearing age,~* morbid obesity,~* drug allergy,contra-indication to succinylcholine, rocuronium, sugammadex, propofol, remifentanil,~* history of central neurological or brain damage,~* psychotropic treatment,~* pacemaker,~* renal failure,~* disease of the neuromuscular junction.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- succinylcholine (Type: ACTIVE_COMPARATOR): Succinylcholine 1 mg/kg and a second dose if necessary.
- Rocuronium (Type: EXPERIMENTAL): rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Persons who have provided written informed consent~* Age \> 18 years~* Patients with type 2 diabetes treated with insulin using a basal / bolus strategy for at least 6 months~* Doses of insulin \> 0.7 U / Kg / d~* HbA1c ≥ 7.5 %~* Without OAD for at least 4 weeks (sulfamides, Incretines, glinides, acarbose) except Metformin~* BMI ≥ 28.5 kg / m2~* Diabetes diagnosed for at least 10 years~* Patients able to monitor themselves and manage an insulin pump.~Exclusion Criteria:~* Patients treated with glitazones during the 3 months preceding inclusion~* Patients with proliferative ischemic retinopathy not treated by laser~* BMI \< 28.5 kg / m2~* Presence of implantable material ( CI MRI )~* Pacemaker ( CI MRI )~* Pregnancy, breast feeding~* Medically significant physical or psychiatric inability, patients under guardianship or wards of court~* The practice of violent sports~* Poor conditions of hygiene~* Professional environment of extreme cold or heat.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intensified multiple injections (Type: OTHER): None
- Pumps (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Guided Imagery and Music Therapy on Post-Operative Recovery After Gynecological Oncology Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects will include women who are being seen at the Women's Health Center by the Gynecological Oncology group at the University of Minnesota (UMMC). These women will be considered for inclusion based on their projected surgery: exploratory laparotomy. Subjects will have to have their surgery at the UMMC within 1 month of their clinic visit. Patients may be undergoing surgery for either known cancer (ovarian or uterine) or high suspicion for malignancy.~Exclusion Criteria:~* \< 19 years old~* pregnant~* undergoing a procedure other than laparotomy~* scheduled to be discharged the same day of surgery~* chronic narcotic pain medication users~* if they are currently using or planning on using other complementary alternative medicine (CAM) therapies prior to or after surgery.

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Guided Imagery and Music therapy group (GIMT) (Type: EXPERIMENTAL): Participants will undergo a standardized regimen of peri-operative guided imagery and music therapy guided by CDs (compact disc). The peri-operative regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
- White Noise Group (WN) (Type: ACTIVE_COMPARATOR): Control group (WN) will listen to a CD with white noise. Participants' regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
- No Interventions Group (CP) (Type: ACTIVE_COMPARATOR): Control group (CP) will have no intervention at all and will follow our current peri-operative procedures.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female 18 and older~* IBS-C patients diagnosed on the basis of Rome II criteria~* Ability to comply with the requirements of the entire study~Exclusion Criteria:~* Evidence of structural abnormality of the gastrointestinal tract or disease/conditions.~* Patients with previous gastrointestinal surgery other than appendectomy or cholecystectomy.~* Evidence of cathartic colon or a history of laxative use, that in the investigator's opinion is consistent with severe laxative dependence such that the patient is likely to require or use laxatives during the study~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues